AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04944524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Study NCT05338931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Description: Anti-CD19 Chimeric Antigen Receptor T cell
Study NCT04787354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2/day
Study NCT04787354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130 mg/m2/day
Study NCT04787354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 2,000 mg/m2/day
Study NCT04787354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 2,000 mg/m2/day
Study NCT04833595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Description: Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
Study NCT04833595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness practice
Description: Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
Study NCT05084898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far-UVC light as an additional method of disinfection
Description: Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
Study NCT04783805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conservative management with regular follow-up
Description: Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
Study NCT04783805 — intervention group
Intervention type: PROCEDURE
Intervention: Conization
Description: Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
Study NCT05084898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fluorescent light
Description: Inactive fluorescent light (no additional disinfection)
Study NCT06339970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique
Description: In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
Study NCT06339970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique
Description: In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
Study NCT04702425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOB560
Description: Powder for concentrate for solution for infusion
Study NCT04702425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIK665
Description: Concentrate for solution for infusion
Study NCT05533320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Cap Therapy
Description: Undergo scalp cooling
Study NCT04865380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: 1g IV x 1 dose of Tranexamic Acid administered preoperatively.
Study NCT04901195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT04862689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ringer Perfusion Balloon Catheter
Description: Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
Study NCT05217004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Talk mobile application
Description: The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
Study NCT05533320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05533320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05485623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseNmore FC
Description: Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe.
Study NCT06256263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laryngectomy
Description: pharyngeal repair after total laryngectomy
Study NCT05767827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, lidocaine with adrenaline
Description: Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
Study NCT05767827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, ropivacaine, lidocaine with adrenaline
Description: Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Study NCT05042284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-enteric coated pancreatic enzyme preparation
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
Study NCT05042284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-enteric coated pancreatic enzyme preparation
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
Study NCT06358144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging imagery
Description: Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
Study NCT05217004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEAR Dementia Care mobile application
Description: The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
Study NCT06358144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Imagery (Control)
Description: Participants in the control condition will see the same four product packages, but without any added imagery.
Study NCT06083298 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: patients will be operated under general anesthesia
Study NCT06083298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCP group
Description: patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
Study NCT06083298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISP group
Description: patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
Study NCT06246409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modernized patient instructions
Description: Patients will be given modernized patient instructions prior to radiotherapy treatment.
Study NCT06034249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based VR
Description: Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
Study NCT06034249 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audio
Description: The mindfulness-based audio files for six weeks.
Study NCT05228483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser
Description: CO2 fraction laser
Study NCT05228483 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) with red light illumination
Description: 5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
Study NCT05228483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate (MMF) 0.1% ointment
Description: 0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
Study NCT05669872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose 50Mg/Ml Inj 20Ml
Description: ferric carboxymaltose 1000mg, fixed dose for intervention group
Study NCT05669872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBC
Description: pack RBC transfusion
Study NCT05293626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR082 Injection
Description: The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in > 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in > 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC.
Study NCT05293626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection needle
Description: 19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration.
Study NCT06503380 — intervention group
Intervention type: OTHER
Intervention: No intervenrion.
Description: This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
Study NCT05603598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAP-2 Protein, Human
Description: Intravenous infusion, mixed meal test, ad libitum meal test
Study NCT05603598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEAP-2 Protein, Human
Description: Intravenous infusion, mixed meal test, ad libitum meal test
Study NCT04785924 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imipenem+Relebactam
Description: Antibiotic treatment for KPC producing CRE-containing gram-negative infections
Study NCT06246409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing patient instructions
Description: Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
Study NCT05728138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus CBT
Description: Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
Study NCT05937789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT05937789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides (MCT)
Description: Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04734730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04734730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT05541445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
Study NCT05792917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafolecimab (a modified manufacturing process)
Description: 450mg，SC，single dose
Study NCT05792917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafolecimab (a original manufacturing process)
Description: 450mg，SC，single dose
Study NCT05354687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-group Teaching
Description: The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
Study NCT05354687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed Learning
Description: The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
Study NCT05688488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
Study NCT05688488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C
Description: Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
Study NCT06437470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction technique
Description: All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff.
Study NCT06437470 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blood flow restriction technique
Description: All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff.
Study NCT06343909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip abductor strengthening exercise
Description: in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
Study NCT06343909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsic foot muscle strengthening along with conventional exercises
Description: in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
Study NCT05521789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESB Thoracic
Description: Erector spinae thoracic block with bupivacaine
Study NCT05644704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower extremity and core muscle training
Description: Lower extremity training: single leg balance training Core muscle training: pelvic control training
Study NCT06300164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unripre Carob
Description: The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT04824092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.